Dr. Roach: Providing more information about Repatha for cholesterol

I felt that it just wasn't worth all the aches and pains.
Investor's Business Daily on MSN

Amgen's numbers are out: It gets to keep its cholesterol crown — for now

Amgen widely beat the Street's first-quarter expectations late Thursday, slightly ticking its 2026 guidance higher.
Nasdaq

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Seeking Alpha

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
Tribune Chronicle

Repatha for cholesterol

I’m a 75-year-old woman who’s in very good health. Since my early 50s, I’ve had issues with my cholesterol. My ...
KVOA 4

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha was first approved in 2015 and has since been used by more than 8 million patients globally. 5,6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to ...
Nasdaq

REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...